WHO ICTRP trial
Predictive value of ABCB1 genotypes on dose adjustment of imatinib in patients…
ACTRN12606000117516 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12606000117516 |
|---|---|
| Public title | Predictive value of ABCB1 genotypes on dose adjustment of imatinib in patients with GIST (Gastro-Intestinal Stromal Tumour) and CML (Chronic Myeloid Leukaemia) |
| Scientific title | Predictive value of ABCB1 genotypes on dose adjustment of imatinib in patients with GIST(Gastro-Intestinal Stromal Tumour) and CML (Chronic Myeloid Leukaemia) |
| Primary sponsor | Investigator Initiated - A/Professor Howard Gurney and Dr Josef Klumpen |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | Not Applicable |
| Countries | Australia |
| Conditions | Patients revieving treatment with imatinib, currently CML (Chronic Myeloid Leukaemia) and GIST (Gastro-Intestinal Stromal Tumour); Patients revieving treatment with imatinib, currently CML (Chronic Myeloid Leukaemia) and GIST… |
| Interventions | The study will correlate the toxicity-adjusted dose of imatinib after 3 months of therapy with polymorphisms of drug elimination genes, particularly ABCB1 (MDR1). Patients will be asked to give a single blood sample for genotyping (at any… |
| Registration date | Mar 4, 2006 |
| Target size | 300 |
| Secondary IDs | HGWH0006 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: